|Articles|December 6, 2022
Further Discussion on Plasmids to Establish Release Specifications Using a Risk-Based Approach to Manage Supply
Author(s)Eurofins
A panel of experts from bio/pharmaceutical companies discuss plasmids to establish specifications using a risk-based approach to manage supply, including the response to cell & gene therapy industry feedback, future outlook and re-evaluating plasmid risks.
Related Content
Sponsored Content
Trending on Pharmaceutical Technology
1
GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing
2
How a 63-Patient Trial Delivered an FDA Approval
3
Ask the Expert: Complying with Standards
4
What Does Overton's FDA Nomination Mean for Drug Reviews?
5